Dozens of cases verify the efficacy of unique compounds
Thanks to the pioneering work of Luminec Executive Advisor Dr. Susana Alcázar-Leyva, Luminec’s X-2™ and CRO-50™ formulations have been used successfully in treating Coronavirus patients and those with other serious illnesses throughout the world.
In addition to COVID-19, the X-2 and CRO-50 compounds – often combined with Luminec’s core technologies, Triamino™ and TAFA400™, and the revolutionary delivery system PH-713™ – have been used to treat over 50,000 respiratory problems, heart conditions, diabetes, cancers, and myriad other health issues over the past 50 years.
One recent patient who agreed to be identified, Christine Munro of Cambridge, England, saw her Stage 4 malignant melanoma reduced to an undetectable level, thanks to a variety of approaches, including X-2 and CRO-50. As she told a reporter for her local newspaper, “I just went in and [one of her doctors] said, ‘I’ve got some good news; we can’t see it on the scan. It has gone.’
“I was on end-of-life care. I have the letters to prove it. To be told they can no longer see it is just a dream come true. The doctors asked what I was doing. They were amazed, too.”
“Dr. Alcázar-Leyva’s exciting work is just the latest example of Luminec’s commitment to bringing simple, natural, effective – and economical – healthcare solutions to the world,” said Luminec Chief Scientific Officer Stephen Holt, MD, DSc, PhD. “The mission of our company, as articulated years ago by company cofounder Steven R. Schutt – the scientist who developed Triamino and TAFA-400 – is to transform the health of people around the globe, especially those in underdeveloped third-world countries. We are proud that X-2 and CRO-50 contribute to that effort.”
“The results of our treatments have exceeded my expectations,” said Dr. Alcázar-Leyva. “Based on the performance of X-2 and CRO-50 in our patients so far, I’m confident that we can make a significant contribution to the mitigation of the horrible COVID-19 pandemic, just as we have to a wide variety of other conditions.”
In addition to her role with Luminec Pharmaceuticals, Dr. Alcázar-Leyva is a founding director of the prestigious Hans Selye Scientific Research Institute, and cofounder and director of the Heberto Alcázar-Montenegro Gerontology School (cofounded by, and named for, her father), and of the Albert Szent-Györgyi Gerontology Center.
About Luminec Pharmaceuticals
Headquartered in Carlsbad, CA, Luminec Pharmaceuticals offers a unique array of all-natural OTC products and clinical services for both humans and animals. Luminec’s products are based on proprietary natural antibiotic, antifungal, antimicrobial formulations combined with a cutting-edge delivery system that significantly improves the absorption of those formulations.
Luminec Pharmaceuticals is a wholly owned subsidiary of Luminec Holdings, Inc., a private company.